Publication Topic

Gentry R, Greene T, Granzen A, Thompson CM. Formaldehyde and leukemia: A case study using the IPCS MOA and human relevance frameworks. Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Vincent MJ, Kozal SJ, Thompson WJ, Maier A, Dotson GS, Best EA, Mundt KA. 2019. Ethylene oxide: Cancer evidence integration and dose-response implications. Dose Response 17(4):1559325819888317; doi: 10.1177/1559325819888317. PMID:3185323510.

Borghoff S, Wikoff D, Urban JD, Rager JE. A systematic approach to identify plausible mode-of-actions (MOA) for an increased incidence of lung tumors in mice with chronic exposure to 4-methylimidazole (4-MEI). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.

Burns AM, Benson SM, Best E, Hollins DM, Finley BL. An ecological epidemiology investigation of talc consumption in the US and trends in female cancer rates. Poster presentation at Society of Toxicology 57^th Annual Meeting, San Antonio, TX, 2018.

Frankenfeld CL, Hakes J, Leslie TF. All-cancer and cancer-specific mortality is associated with black race segregation in the United States: Mortality Disparities in American Communities data. American Association for Cancer Research: Poster presentation to The Science of Cancer Health Disparities, 2018.

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Finley BL, Benson SM, Marsh GM. 2017. Cosmetic talc as a risk factor for pleural mesothelioma: A weight of evidence valuation of the epidemiology. Inhal Toxicol 29(4):179–185.

Finley BL, Scott PK, Burns AM, Marsh GM. Does PCB exposure cause non-Hodgkins lymphoma? A weight of evidence evaluation. Late-breaking poster presentation at Society of Toxicology 56^th Annual Meeting, Baltimore, MD, 2017.

Finley BL, Donovan ED, Kovochich M, Paustenbach DJ, Urban AM. Perineal use of cosmetic talc as a risk factor for ovarian cancer: A weight-of-evidence evaluation. Abstract #1288. Poster presentation at Society of Toxicology 56^th Annual Meeting, Baltimore, MD, 2017.

Cui Y, Li J, Weng L, Wirbisky SE, Freeman JL, Liu J, Liu Q, Yuan X, Irudayaraj J. 2016. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget 7(49):81698–81714; doi: 10.18632/oncotarget.13173.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA, et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181. doi: 10.1007/s12029-016-9809-5.

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4:1 http://dx.doi.org/10.4172/2329-6917.1000208

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7): 500–503.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 101(12):1524–1533. doi: 10.3324/haematol.2016.144311.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.